GlobeNewswire by notified

Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing

Share

COLUMBUS, Ohio, Jan. 11, 2023 (GLOBE NEWSWIRE) --  Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. Tryten is based in Langley, British Columbia.

A Media Snippet accompanying this announcement is available by clicking the image or link below

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

Capsa’s purchase of Tryten is the company’s second major brand acquisition in the last year, and strategically addresses several healthcare industry trends. Today’s hospitals and clinics are striving to provide expanded virtual care, improved patient engagement and efficient mobility for small medical devices; Capsa now has the widest product portfolio to support these needs.

Tryten is an industry leader known for thoughtful, simple, slim-profile cart designs to support virtual care and improved patient experience in practically any care setting. In addition, Tryten provides customized cart solutions to medical device companies and healthcare solution providers so they can safely and effectively mobilize their technology devices for better clinical workflows and improved patient care delivery.

Tryten mobile computing carts are applicable for a host of applications including:

  • Ultrasound
  • Cardiology
  • Endoscopy
  • Tele Stroke
  • Virtual Interpreting/translation
  • Patient observation
  • Electronic health records
  • Patient registration and vital signs

“After observing the rapid adoption of virtual care and the expanded use of tablets and innovative technologies in healthcare, we decided that now was the right time to invest in expanding Capsa’s point-of-care solutions portfolio,” says Eric Webb, Capsa Healthcare CEO. “Tryten is a fresh, relatively new brand in the mobile workstation space, and we have every reason to believe its inclusion will help our clinical customers deliver the best care to patients in whatever setting they work.”

Understanding that computing workstation needs differ across care environments, Capsa Healthcare offers an extensive portfolio of mobile computing workstations, wall mount arm platforms, and solutions that support modern medication management. Capsa’s breadth of products include its Trio, M38e, MedLink, T7, and SlimCart mobile workstations, as well at its leading V6 wall mount solution. The addition of Tryten’s mobile carts is complementary to Capsa’s point-of-care solutions and opens a new and exciting opportunity to advance both virtual and patient-centered healthcare delivery.

“Tryten and Capsa have both worked diligently toward a similar overarching goal to improve the clinician’s ability to efficiently deliver quality care to the patient. Bringing the Tryten product line into Capsa’s portfolio is a natural fit culturally and functionally,” says Tony Janzen, Tryten CEO. “We’re excited for what the future holds as our team joins the expanding Capsa organization.”

AboutCapsaHealthcare

Capsa Healthcare is a worldwide leader in developing and delivering innovative healthcare solutions for a wide spectrum of care providers. With 60+ years of experience, Capsa Healthcare offers a unique ability to meet the demands of diverse healthcare environments and offers a broad range of products including medication carts, medical carts, mobile computing, and pharmacy automation solutions. Headquartered in Columbus, OH, and with a quickly growing global presence, Capsa Healthcare has 400+ employees with management, sales, and production offices throughout the world. To learn more visit www.capsahealthcare.comor call 800-437-6633.

AboutTryten

Tryten Technologies Inc., based in Langley, British Columbia, designs and manufactures lightweight, versatile mobile cart solutions for a wide range of applications including video remote interpreting (VRI), virtual rounding, tele sitting, EHR workstations, and telemedicine. Tryten’s goal is to improve the patient and provider experience while reducing the cost of care, enabling value-based care where and when it is needed most.

Press Contact:
Liz Delp
Senior Marketing Manager | Capsa Healthcare
Columbus, OH U.S.A.
614.729.8012 | ldelp@capsahealthcare.com

Photography Available


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

SKEL fjárfestingafélag hf.: Amendment to the financial calendar and previously disclosed information4.2.2023 19:13:54 CET | Press release

The audit of SKEL’s financial statements for the year 2022, which has not been finalized, has resulted in a change of its presentation due to the company‘s transition into an investment company. Shares in subsidiaries were capitalized according to the equity method until year end 2021 but are recognised at fair value through profit or loss from the beginning of 2022. This results in a previously unrealized fair value change from 2021 of ISK 2.6 billion that was formerly accounted for directly through equity, will instead be recognised in the income statement for 2022. This change of presentation has no effect of previously announced equity for year-end 2022 of ISK 33.0-33.5 billion. Further, this does not alter the company’s ability to pay dividend. The company‘s estimated earnings net of tax will, however, increase by ISK 2.6 billion and amount to ISK 17.1-17.6 billion instead of ISK 14.5-15.0 billion as was previously announced on 31 January 2023. The company has decided to change th

City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing4.2.2023 05:18:05 CET | Press release

Vacaville high school students explore local career opportunities to honor National Career Technical Education Month VACAVILLE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- February is National Career Technical Education (CTE) Month, and the City of Vacaville joined the celebration by hosting a field trip for 58 Vacaville high school students February 3. The field trip included several locations around Vacaville and Solano County to explore advanced manufacturing and biotechnology. Every February, the Association for Career and Technical Education encourages communities to celebrate CTE Month, to raise awareness of the role that CTE has in readying learners for college and career success. This is also a time when the City of Vacaville recognizes and celebrates the contributions and achievements of community CTE partners including Solano Community College (SCC) and The Workforce Development Board of Solano County. “This field trip is an excellent opportunity for Vacaville’s young people to

Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®4.2.2023 00:30:00 CET | Press release

In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like abscesses that can lead to open wounds and irreversible scarring in the most intimate parts of the body2,3 There is only one approved therapy for HS and many patients, even those on treatment, still experience uncontrolled symptoms4 Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in moderate-to-severe hidradenitis suppurativa (HS)1. In two of the largest Phase III trials

Maha Energy meddelar reserv- och resursrapport per 31 december 20223.2.2023 21:45:00 CET | Pressemelding

McDaniel & Associates Consultants Ltd. (“McDaniel”) har genomfört sin första utvärdering av Maha Energy AB:s (publ) (”Maha” eller ”Bolaget”) reserver och resurser. Väsentliga förändringar från föregående års reserv- och resurssiffror är hänförliga till: att den tidigare annonserade utfarmningen och Joint Operating Agreement avtalet med Mafraq Energy LLC avseende Block 70 i Oman slutförs. Maha är operatör på Block 70 och Mahas licensandel minskar till 65 procent till följd härav.att den tidigare offentliggjorda transaktionen avseende den förväntade avyttringen av Mahas brasilianska verksamhet och följaktligen bolagets olje- och gastillgångar, där försäljningsavtalet undertecknades den 27 december 2022, resulterar i att inga reserver redovisas för fälten Tie och Tartaruga. Mahas reserver1 per 31 december 2022 2022 Maha Energy AB bruttoreserver före skatt (miljoner fat)KategoriTillgångar i USAMafraqTotalt1P1,340,421,762P2,740,523,263P3,590,624,21 De huvudsakliga förändringarna i årets res

Maha Energy AB announces December 31st, 2022 Reserve Report and Resource Report3.2.2023 21:45:00 CET | Press release

McDaniel & Associates Consultants Ltd. (“McDaniel”) has completed their first annual reserve and resource determination for Maha Energy AB (publ) (“Maha” or the “Company”). Main changes from last year’s reserves and resources numbers are related to: the successful completion of the previously announced Farm Out and Joint Operating Agreement with Mafraq Energy LLC for Block 70 in Oman, in which Maha is the Operator of the block and reduces its working interest (“WI”) to 65%;The previously disclosed transaction involving the expected divestment of Maha’s Brazilian entity and, consequently, its oil and gas assets, which SPA was signed on December 27th,2022, and is why no reserves are being reported for Tie and Tartaruga fields. Maha Reserves1 as of 31st December 2022 2022 Maha Energy AB Company Gross Reserves before income tax (Million barrels)CategoryUS Assets MafraqTotal1P1.340.421.762P2.740.523.263P3.590.624.21 The main changes to this year’s reserve volumes are: A reduction of 1.0 mil